Pharmaceutical

FibroBiologics and Charles River link for chronic disease therapies manufacture

FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies.

Oct 22, 2024 - 04:00
FibroBiologics and Charles River link for chronic disease therapies manufacture
FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies.
Read the original article

Tags:

Previous Article

ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology

Next Article

FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Apr 17, 2024

Medtronic isn’t afraid of Wegovy’s potential to disrupt

Medtronic isn’t afraid of Wegovy’s potential to disrupt

Nov 23, 2023

STAT+: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder

STAT+: Mirum’s Chenodal succeeds in late-stage trial fo...

Oct 2, 2023